Pretreatment Serum Gh Levels and Cardio-Metabolic Comorbidities in Acromegaly; Analysis of Data From Iran Pituitary Tumor Registry Publisher



Hedayati Zafarghandi L¹ ; Khamseh ME² ; Fooladgar M¹ ; Mohseni S³ ; Qorbani M^{4, 5} ; Madani NH² ; Hemmatabadi M⁶ ; Mohajeritehrani MR³ ; Shirzad N³ Show Affiliations
Source: Journal of Diabetes and Metabolic Disorders Published:2020

Abstract

Background: Acromegaly is a rare chronic disabling disorder, in which growth hormone (GH) excess is associated with a range of clinical features and systemic complications. The present study aims to evaluate the association between pretreatment basal GH levels as well as GH levels after oral glucose tolerance test (OGTT) and cardio-metabolic comorbidities, including diabetes mellitus (DM), left ventricular hypertrophy (LVH) and hypertension (HTN) in patients with active acromegaly. Methods: A retrospective study of the medical records regarding 113 patients with acromegaly registered at two main centers of Iran Pituitary Tumor Registry during 2011–2018. Results: The mean age of the patients was 42.76 ± 11.6 (range: 21–72) years. Mean GH level at baseline was 21 ng/ml while nadir GH levels at 60 and 120 min after glucose were 6.95 and 9.05 ng/ml, respectively. There was a negative correlation between age and basal serum GH level (r= -0.196, p = 0.038). Hypertension and diabetes mellitus were detected in 26.8% and 19.7% of the patients. A positive correlation was detected between serum GH values and systolic blood pressure. There was not any significant difference in basal GH and GH post OGTT regarding DM, Diastolic blood pressure and LVH. Conclusions: Our findings suggest that pretreatment basal GH levels are higher in younger patients with acromegaly. Furthermore, higher GH values (0, 60 and 120 min) during OGTT are associated with higher systolic blood pressure. A comprehensive evaluation of this population regarding comorbidities should be performed. © 2020, Springer Nature Switzerland AG.